Lanreotide for Lung NETs – SPINET Trial

Somatuline (Lanreotide)

There’s been a lot of action in the area of what is termed Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs).  It can therefore sometimes appear that Lung NETs are the poor relation.  There are certainly some unmet needs in this area of the anatomy including a lack of research.  Thus far, no prospective trials specifically for patients with lung NETs appear to have been reported.

However, there has been some recent movement. Last year, the use of Afinitor (Everolimus) was approved for progressive, non-functional NET of GI or Lung origin.

SPINET Trial for Lung NETs

In late 2016, I tipped you off about an Ipsen sponsored trial for Lung NETs involving Lanreotide (Somatuline) SPINET is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the efficacy and safety of Lanreotide plus “Best Supportive Care” (BSC) versus placebo plus BSC for the treatment of well-differentiated, metastatic and/or unresectable, typical or atypical lung NETs.   The aim of the SPINET study is to evaluate the safety and antitumor efficacy of Lanreotide 120 mg in patients with advanced lung NETs.  I suspect that many Lung NET patients are already receiving somatostatin analogues (Octreotide/Lanreotide) but prescribed only for syndrome/symptom control.

SPINET is now recruiting in many locations (see below).

The countries involved in the SPINET trial are as follows (see the location details here in the trials document). Please also check the inclusion and exclusion criteria.

USA (21 locations)

Austria (1 location)

Canada (3 locations)

Denmark (2 locations – none recruiting yet)

France (7 locations)

Germany (4 locations)

Italy (5 locations – only one recruiting so far)

Netherlands (2 locations – none recruiting yet)

Poland (6 locations – none recruiting yet)

Spain (4 locations – only 2 recruiting so far)

UK (6 locations – only one recruiting so far)

In addition to the trial document linked above, you can read more about the SPINET trial here with commentary from a well-known NET Specialist – Dr Diane Reidy-Lagunes, who is the principal investigator for the trial.

How do I get on the trial?

You may be interested in this organisation – Trialbee.  They are a company helping Ipsen to raise awareness of the SPINET trial using a cloud based platform to connect patients, investigators and sponsors (I’ve authenticated their participation with Ipsen).  There is no fee for using their services.  There’s a useful questionnaire which can help you decide if this trial is for you – here.

Please note, if you are concerned about participating in clinical trials, you should always consult your specialist for advice.  

Thanks for reading

 

If you are a patient advocate or an advocate organisation, please share with your communities in order that Lung NET patients are at least made aware of the trial.

 

Ronny

Don’t forget to VOTE FOR ME in the 2017 WEGO Health Awards – click here

Hey, I’m also active on Facebook.  Like my page for even more news.

Disclaimer

My Diagnosis and Treatment History

Most Popular Posts

Sign up for my twitter newsletter

Check out my Podcast (click and press play)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

community_titled_transparent_2013-10-22

Author: Ronny Allan

Facebook: https://m.facebook.com/NETCancerBlog and https://m.facebook.com/RonnyAllanBlog twitter: @ronnyallan1 twitter: @netcancerblog

2 thoughts on “Lanreotide for Lung NETs – SPINET Trial”

Leave a Reply